Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept

Journal of Rheumatology

Volumn 31, Issue 12, 2004, Pages 2356-2359

  Haraoui, Boulos ^a,g   Keystone, Edward C ^b   Thorne, J Carter ^c   Pope, Janet E ^d   Chen, Isaac ^e   Asare, Charles G ^f   Leff, Jonathan A ^f  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Arthritis Program Research Group

^d MCMASTER UNIVERSITY   (Canada)

^e Global Quality Analytical Development New Products

^f AMGEN INC   (United States)

^g NOTRE DAME HOSPITAL   (Canada)

Author keywords

Antirheumatic agents; Etanercept; Infliximab; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAIR LOSS; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 10044253359     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Arnett FC, Edworthy SW, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
2. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
3. Enbrel® package insert. Seattle, WA: Immunex Corporation; 2003.
4. Brocq O, Plubel Y, Breuil V, et al. Switch étanercept-infliximab dans la polyarthrite rhumatoide: 14 patients sur 131 traités par anti-TNFα. Presse Med 2002;31:1836-9.
5. Durez P, Nzeusseu A, Houssiau FA, Devogelaer JP. Rechallenge of anti-TNF therapy with etanercept in a patient suffering from severe rheumatoid arthritis and tuberculosis complicating infliximab therapy, a long term follow-up [abstract]. Ann Rheum Dis 2002;61 Suppl 1:386.
6. Erra A, Moreno E, Guanhon L, Urruticoechea A, Tomás C, Barceló P. Experience in the switch from infliximab to etanercept, or vice versa, in rheumatoid arthritis patients [abstract]. Ann Rheum Dis 2002;61 Suppl 1:379.
7. Van Vollenhoven RF, Harju A, Brannemark S, Klareskog L. Switching between etanercept and infliximab: data from the Stockholm TNF-alpha antagonist registry (STURE) [abstract]. Ann Rheum Dis 2002;61 Suppl 1:54.
8. Buch MH. Do patients with rheumatoid arthritis with high disease activity on infliximab demonstrate improvement on etanercept? [abstract]. Ann Rheum Dis 2003;62 Suppl 1:181.
9. Barone D, Krantz C, Lambert D, Maggiora K, Mohler K. Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement-dependent fashion [abstract]. Arthritis Rheum 1999;42 Suppl 9:S90.
10. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
11. Remicade® package insert. Malvern, PA: Centocor, Inc; 2003.
12. St. Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9.
13. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
14. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003;62:561-4.
15. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003;48:780-90.
16. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.